Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells

Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells

Investigations from multiple laboratories support the existence of melanoma initiating cells (MICs) that potentially contribute to melanoma's drug resistance. ABT-737, a small molecule BCL-2/BCL-XL/BCL-W inhibitor, is promising in cancer treatments, but not very effective against melanoma, with...

Full description

Bibliographic Details
Main Authors: Mukherjee, Nabanita, Reuland, Steven N., Lu, Yan, Luo, Yuchun, Lambert, Karoline, Fujita, Mayumi, Robinson, William A, Robinson, Steven E, Norris, David A., Shellman, Yiqun G.
Format: Online
Language:English
Published: 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323853/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323853/

Similar Items